What is GDNF?
GDNF is a small protein that protects and restores the function of a wide range of neurons and glia, and has been shown to be beneficial in the clinic for Parkinson's Disease and in pre-clinical studies for Motor Neurone Disease and Spinal Cord Injuries. We are harnessing GDNF’s restorative properties using a proprietary gene therapy delivery technology and a superior proprietary b-GDNF isoform.
About US
Innervate Therapeutics Ltd (ITL) is positioned to maximise the neurorestorative potential of GDNF using patent protected, novel and scalable delivery methods and technology for which it has licenced exclusive use for GDNF gene therapy applications. With ONE proprietary gene platform offering THREE potential life-changing treatments
Our Team
Prof. Steven Gill - CSO Honorary Professor of Neurosurgery at the University of Bristol and a Consultant Neurosurgeon at Southmead Hospital, Bristol. Steven pioneered DBS to treat Parkinson’s disease and tremor. Carried out the first clinical trial of infusing, GDNF, directly into the brain and demonstrated reversal of Parkinson’s disease.Multiple patented inventions.
Prof. Neil Barua – CMO Neil is a Consultant Neurosurgeon specialising in brain tumour surgery (neuro-oncology), DBS for movement disorders and degenerative spinal disease. He completed his neurosurgical training in Bristol ,Plymouth and Montpellier, France. He is now lead for neuro-oncology surgery at North Bristol NHS Trust.
​
Our Progress
Our novel gene therapy to treat MND is in advanced pre-clinical development and a first-in-man study is planned for 2027. Pre-clinical development of the same gene therapy platform to treat SCI will commence during 2025, with the aim of initiating a first-in-man study for this indication in 2027 also. A third indication of the gene therapy platform to treat PD will enter pre-clinical development imminently.
We are currently seeking investment to finance these exciting initiatives and would welcome enquiries from investors interested to learn more about our opportunity. Follow the link below to view a non-confidential Information Memorandum and contact Conor McCullough at Beltrae Partners Limited for further information email
​
